Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.

Blood - 1 Jun 2007

Yu Duonan, Carroll Martin, Thomas-Tikhonenko Andrei

Abstract excerpt

The proapoptotic function of p53 is thought to underlie most anticancer modalities and is also activated in response to oncogenic insults, such as overexpression of the Myc oncoprotein. Here we generated tractable B lymphomas using retroviral transduction of the MYC oncogene into hematopoietic ce...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen Antagonists
Share to Genes, p53
Share to Hematopoietic Stem Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, B-Cell

Share to Protease Inhibitors

Share to Proteasome Inhibitors

Share to Proto-Oncogene Proteins c-mdm2

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 17284530
DOI: 10.1182/blood-2006-10-050294
PMCID: PMC1885530

Genes

MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17284530-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.PMID 17284530Read ↗

Targeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapySemantic proximity Read ↗

Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies.Semantic proximity Read ↗

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.Semantic proximity Read ↗

Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.Semantic proximity Read ↗

Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer TherapySemantic proximity Read ↗

Dysfunction of the TP53 tumor suppressor gene in lymphoid malignanciesSemantic proximity Read ↗

MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugsSemantic proximity Read ↗

Cross‐talk between Myc and p53 in B‐cell lymphomasSemantic proximity Read ↗

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma CellsSemantic proximity Read ↗

MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt LymphomaSemantic proximity Read ↗

Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphomaSemantic proximity Read ↗

TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.